SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 26.04 |
| Enterprise Value ($M) | 4.83 |
| Book Value ($M) | 32.99 |
| Book Value / Share | 1.25 |
| Price / Book | 0.79 |
| NCAV ($M) | 31.17 |
| NCAV / Share | 1.19 |
| Price / NCAV | 0.84 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.70 |
| Return on Assets (ROA) | -0.27 |
| Return on Equity (ROE) | -0.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.36 |
| Current Ratio | 5.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 81.54 |
| Assets | 83.36 |
| Liabilities | 50.36 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Novo Holdings A/S | 0.00 | -100.00 | |
| 13G/A | Redmile Group, LLC | 7.90 | -26.34 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 21,688 | 79,796 | 27.18 | |
| 3,665 | 57,365 | 6.39 | |
| 18,271 | 142,334 | 12.84 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KRYS – Krystal Biotech, Inc. | KURA – Kura Oncology, Inc. |
| KYTX – Kyverna Therapeutics, Inc. | LXRX – Lexicon Pharmaceuticals, Inc. |
| LYEL – Lyell Immunopharma, Inc. |
Financial data and stock pages provided by
Fintel.io